BioSpace News Archive

Drug Development

InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum

InflaRx N.V. (Nasdaq: IFRX) announced today that the first patient has been dosed in its Phase III study investigating the efficacy and safety of vilobelimab in ulcerative PG, a rare neutrophilic and inflammatory skin disease characterized by destructive, painful cutaneous ulcers.

November 6, 2023
·
9 min read
BioCapital

Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE® Technology

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced a global non-exclusive collaboration and license agreement with Halozyme Therapeutics Inc.

November 6, 2023
·
4 min read
Business

HALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme” or the “Company”) today reported its financial and operating results for the third quarter ended September 30, 2023 and provided an update on its recent corporate activities and outlook.

November 6, 2023
·
22 min read
Business

Rocket Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Progress

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) today reported financial results for the quarter ending September 30, 2023, and updates from the Company’s key pipeline developments, business operations and upcoming milestones.

November 6, 2023
·
12 min read
Business

Vertex Reports Third Quarter 2023 Financial Results

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2023, raised full year 2023 guidance for product revenue and reiterated full year 2023 guidance for operating expenses.

November 6, 2023
·
26 min read
Business

ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates

ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today reported financial results and operational updates for the quarter ended September 30, 2023.

November 6, 2023
·
10 min read
Business

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the third quarter ended September 30, 2023.

November 6, 2023
·
19 min read
Business

Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights

Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today reported financial results for the quarter ended September 30, 2023, and recent business highlights.

November 6, 2023
·
19 min read
Genetown

Aura Biosciences Announces Proposed Public Offering of Common Stock - November 06, 2023

Aura Biosciences, Inc., a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, announced the launch of an underwritten public offering of its common stock.

November 6, 2023
·
5 min read
Business

ATEC Reports Third Quarter 2023 Financial Results and Raises Full Year 2023 Adjusted EBITDA Guidance

Alphatec Holdings, Inc., a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced financial results for the quarter ended September 30, 2023, and recent corporate highlights.

November 6, 2023
·
11 min read